{"id":"sustanon-250","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Acne"},{"rate":"10-20%","effect":"Hair loss"},{"rate":"5-10%","effect":"Elevated liver enzymes"},{"rate":"5-10%","effect":"Mood changes"},{"rate":"5-10%","effect":"Sleep apnea"}]},"_chembl":{"chemblId":"CHEMBL3663534","moleculeType":"Small molecule","molecularWeight":"402.38"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It contains a mixture of four different testosterone esters, which are slowly released into the bloodstream over time, providing a sustained increase in testosterone levels. This helps to alleviate symptoms of low testosterone, such as fatigue, decreased libido, and osteoporosis.","oneSentence":"Sustanon 250 is an oil-based injectable testosterone blend used to treat low testosterone levels in men.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:58.681Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypogonadism"},{"name":"Delayed puberty"}]},"trialDetails":[{"nctId":"NCT07481942","phase":"","title":"Body Composition Assessment in Transgender Population.","status":"COMPLETED","sponsor":"Celia Bañuls","startDate":"2017-01-01","conditions":"Transgender","enrollment":70},{"nctId":"NCT04798469","phase":"PHASE2","title":"Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-01-10","conditions":"Opioid Use, Pain, Hypogonadism, Male","enrollment":150},{"nctId":"NCT07143279","phase":"EARLY_PHASE1","title":"Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life","status":"RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2026-02-11","conditions":"Hypotestosteronism, Palliative Care","enrollment":20},{"nctId":"NCT02090114","phase":"PHASE2","title":"RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-08-25","conditions":"Prostate Cancer","enrollment":112},{"nctId":"NCT05417035","phase":"NA","title":"Pubertal Replacement In Boys Study Nebido and Testoviron Depot Treatment","status":"COMPLETED","sponsor":"NU-Hospital Organization, Sweden","startDate":"2014-06-01","conditions":"Puberty Delayed","enrollment":27},{"nctId":"NCT01533129","phase":"PHASE4","title":"The Effect of Testosterone Replacement on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Hypogonadotrophic Hypogonadism","status":"COMPLETED","sponsor":"Gulhane School of Medicine","startDate":"2008-08","conditions":"Hypogonadotrophic Hypogonadism","enrollment":106},{"nctId":"NCT04207684","phase":"PHASE1","title":"Generation of Biological Samples Positive to Testosterone for Anti-doping Control","status":"COMPLETED","sponsor":"Parc de Salut Mar","startDate":"2020-02-04","conditions":"Healthy Volunteers","enrollment":4},{"nctId":"NCT03054168","phase":"PHASE3","title":"Systemic Hormones and Muscle Protein Synthesis","status":"UNKNOWN","sponsor":"University of Nottingham","startDate":"2016-12-15","conditions":"Sarcopenia, Muscle Hypotrophy, Muscle Atrophy","enrollment":34},{"nctId":"NCT01797718","phase":"PHASE2, PHASE3","title":"Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2013-10","conditions":"Constitutional Delay of Growth and Puberty","enrollment":35},{"nctId":"NCT02171390","phase":"PHASE4","title":"Endothelial Dysfunction, Inflammation and Insulin Resistance in Congenital Hypogonadism and Effect of Testosteron Replacement Therapy","status":"COMPLETED","sponsor":"Gulhane School of Medicine","startDate":"2008-08","conditions":"Hypogonadotrophic Hypogonadism","enrollment":130},{"nctId":"NCT02111434","phase":"PHASE4","title":"Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment","status":"COMPLETED","sponsor":"Gulhane School of Medicine","startDate":"2013-07","conditions":"Hypogonadism","enrollment":150},{"nctId":"NCT02111473","phase":"PHASE4","title":"The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism","status":"COMPLETED","sponsor":"Gulhane School of Medicine","startDate":"2009-05","conditions":"Hypogonadism","enrollment":49},{"nctId":"NCT01758094","phase":"","title":"Plasma RBP Levels in Patients With Idiopathic Hypogonadotrophic Hypogonadism","status":"COMPLETED","sponsor":"Gulhane School of Medicine","startDate":"2008-01","conditions":"Idiopathic Hypogonadotropic Hypogonadism","enrollment":25},{"nctId":"NCT01601327","phase":"PHASE4","title":"Effects of Medications in Patients With Hypogonadism","status":"COMPLETED","sponsor":"Gulhane School of Medicine","startDate":"2008-01","conditions":"Idiopathic Hypogonadotropic Hypogonadism","enrollment":119},{"nctId":"NCT01454011","phase":"PHASE4","title":"The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups","status":"COMPLETED","sponsor":"Gulhane School of Medicine","startDate":"2008-09","conditions":"Secondary Hypogonadism","enrollment":140},{"nctId":"NCT01107067","phase":"PHASE4","title":"Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism","status":"COMPLETED","sponsor":"Gulhane School of Medicine","startDate":"2008-06","conditions":"Hypogonadism","enrollment":32}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DRUG ABUSE"},{"count":2,"reaction":"HYPERSENSITIVITY"},{"count":2,"reaction":"PROSTATE CANCER"},{"count":2,"reaction":"VENTRICULAR TACHYCARDIA"},{"count":1,"reaction":"ADENOCARCINOMA"},{"count":1,"reaction":"ATRIAL FIBRILLATION"},{"count":1,"reaction":"BILIARY SEPSIS"},{"count":1,"reaction":"BLOOD PRESSURE INCREASED"},{"count":1,"reaction":"BREAST CANCER"},{"count":1,"reaction":"BRONCHITIS"}],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Testosterone"],"phase":"phase_3","status":"active","brandName":"Sustanon 250","genericName":"Sustanon 250","companyName":"Jules Bordet Institute","companyId":"jules-bordet-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sustanon 250 is an oil-based injectable testosterone blend used to treat low testosterone levels in men. Used for Hypogonadism, Delayed puberty.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}